NEW YORK (TheStreet) -- Danaher (DHR) - Get Reporthas been in a steady uptrend for years, and traders expect further gains.

OptionMonster's tracking programs detected the purchase of 1,200 June 87.50 calls for $4.35. An equal number of March 80 calls was sold for $7.70, but volume was below open interest. That suggests an existing long position was closed and rolled to the higher strike.

Calls lock in the price where investors can buy a stock, which lets them play for a rally with limited cost. (See our education section.) That helps manage risk and can also result in significant leverage on a percentage basis.

On Oct. 31, for instance, we cited buying in the December 85. They almost doubled two weeks later, even with the shares gaining only modestly.

Danaher rose 0.17% to $86.88 yesterday, and is up 21% since mid-October. While technically an industrial company, Danaher has a heavy focus on medical and life-science products.

Overall option volume was five times greater than average in the session.

(A version of this post appeared on InsideOptions Pro yesterday.)

TheStreet Ratings team rates DANAHER CORP as a Buy with a ratings score of A-. TheStreet Ratings Team has this to say about their recommendation:

"We rate DANAHER CORP (DHR) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, increase in stock price during the past year and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity."

You can view the full analysis from the report here: DHR Ratings Report